Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 9.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 34,186 shares of the biotechnology company’s stock after selling 3,382 shares during the period. Rhumbline Advisers’ holdings in Arcturus Therapeutics were worth $832,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics in the 1st quarter valued at $40,000. Quest Partners LLC acquired a new position in Arcturus Therapeutics in the 4th quarter valued at $67,000. CANADA LIFE ASSURANCE Co raised its stake in Arcturus Therapeutics by 10.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 1,800 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Arcturus Therapeutics by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,064 shares during the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ARCT shares. Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. HC Wainwright increased their price objective on Arcturus Therapeutics from $60.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Finally, Leerink Partners initiated coverage on Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Buy” and an average target price of $71.40.

Arcturus Therapeutics Stock Up 2.6 %

Shares of NASDAQ:ARCT opened at $21.15 on Tuesday. The business has a fifty day moving average of $21.11 and a two-hundred day moving average of $26.95. The stock has a market cap of $569.61 million, a P/E ratio of -5.41 and a beta of 2.60. Arcturus Therapeutics Holdings Inc. has a 52-week low of $17.52 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. The business had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period in the prior year, the business posted ($1.98) EPS. On average, equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.